Fig. 3.

A specific inhibitor of cPLA₂α reduced both arachidonic acid (AA) and PGE₂ release but did not affect PMN transepithelial migration. A: treatment of A549 cells with PAO1 resulted in a significant increase in the release of AA, which is reduced in a dose-dependant manner by pretreating A549 cells for 2 h with cPLA₂α-specific inhibitor. B: response to PAO1 following a 2-h pretreatment of A549 cells with universal PLA₂ inhibitors ONO-RS-082 (10 μM) or ACA (50 μM) or with the specific cPLA₂α inhibitor (6 μM) is reported as a percentage of the response to PAO1 infection pretreated with vehicle control [0.1% DMSO, which was set at 100% (no inhibitor)]. C: pretreatment of A549 monolayers grown on Transwells with cPLA₂α inhibitor (0.6 to 6 μM) for 2 h had no effect on PAO1-induced polymorphonumclear cells (PMNs) transepithelial migration compared with A549 monolayers pretreated with 0.1% DMSO vehicle control (0 μM). *P < 0.05, statistically significant decrease compared with control using the Student's t-test. Each data point represents an average of at least 3 separate wells. Each above experiment was performed on at least 3 separate occasions yielding similar results.